Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 17/20 | 0.59 |
| ▸ | CTSL | P07711 | 17/20 | 0.59 |
| ▸ | CTSS | P25774 | 15/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576522 | 0.86 | CTSL (0.80) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL6053228 | 0.79 | CTSB (0.51) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576517 | 0.78 | CTSB (0.54) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576707 | 0.75 | CTSB (1.00) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL6053502 | 0.74 | CTSB (0.56) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4577128 | 0.73 | CTSL (0.85) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL6053162 | 0.73 | CTSL (0.49) | CTSBCTSLCTSSCTSK | |
| SCHEMBL6185946 | 0.73 | CTSB (1.00) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576245 | 0.72 | CTSL (0.94) | CTSBCTSLCTSSCTSKCTSD | |
| Balicatib SCHEMBL1587772 | 0.72 | CTSB (1.00) | CTSBCTSLCTSSCTSKCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651238-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | Novartis AG (CH) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014006-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | claimed |